We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00583661
First Posted: December 31, 2007
Last Update Posted: March 15, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Berlin Heart, Inc
Results First Submitted: January 25, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Heart Failure
Cardiomyopathies
Intervention: Device: EXCOR Pediatric

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subject were recruited at pediatric transplant centers by the implanting physicians.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
EXCOR Pediatric Implantation of the EXCOR Pediatric Ventricular Assist Device

Participant Flow:   Overall Study
    EXCOR Pediatric
STARTED   48 
COMPLETED   48 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
EXCOR Pediatric Implantation of the EXCOR Pediatric Ventricular Assist Device

Baseline Measures
   EXCOR Pediatric 
Overall Participants Analyzed 
[Units: Participants]
 48 
Age 
[Units: Participants]
 
<=18 years   48 
Between 18 and 65 years   0 
>=65 years   0 
Age 
[Units: Months]
Median (Full Range)
 64.3 
 (2.6 to 191.8) 
Gender 
[Units: Participants]
 
Female   23 
Male   25 
Region of Enrollment 
[Units: Participants]
 
United States   47 
Canada   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Safety of EXCOR® Pediatric Was Evaluated by Summarizing the Serious Adverse Event Rate Experienced While the Subject Was Supported on the Device.   [ Time Frame: Participants were followed while on device support, an average of 58 days ]

2.  Primary:   Efficacy of the EXCOR® Pediatric Was Estimated by Showing Survival of All Participants Who Were Supported by the Device.   [ Time Frame: Participants were followed while on device support, an average of 58 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Robert Kroslowitz, CEO
Organization: Berlin Heart Inc.
phone: 1-281-863-9700
e-mail: kroslowitz@berlinheart.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Berlin Heart, Inc
ClinicalTrials.gov Identifier: NCT00583661     History of Changes
Other Study ID Numbers: EXCOR® Pediatric
First Submitted: December 20, 2007
First Posted: December 31, 2007
Results First Submitted: January 25, 2012
Results First Posted: March 15, 2013
Last Update Posted: March 15, 2013